2 results about "Humoral immunity" patented technology

The invention relates to a recombinant adenovirus rAd-ORF2-TCE. The recombinant adenovirus rAd-ORF2-TCE is obtained through fusing and connecting an immunogenic protein gene ORF2 of PCV2 (Porcine Circovirus Type 2) and three T lymphocyte epitope (TCE) series genes, and then, recombining to an adenovirus vector. The invention further relates to application of the recombinant adenovirus rAd-ORF2-TCE in porcine viral immunization vaccines. According to the recombinant adenovirus rAd-ORF2-TCE disclosed by the invention, an organism can be effectively stimulated to generate a high-level specific antibody and generate T lymphocyte proliferation, and both the concentration of IFN-gamma in blood serum and the concentration of IL-2 in the blood serum are increased remarkably; compared with ORF2 of separate PCV2, the recombinant adenovirus rAd-ORF2-TCE has the advantage that both humoral immunity level and cellular immunity level of an animal body are increased remarkably.

The invention discloses a cryptosporidium parvum Cp15 recombinant invasive lactic acid bacteria live vector vaccine. The used lactic acid bacteria are lactic acid bacteria expressing staphylococcus aureus invasive cell key protein FnBPA protein through transformation, and have the capability of delivering DNA. The Cp15 recombinant invasive lactic acid bacteria live vector vaccine for preventing cryptosporidiosis parvum is low in production cost, simple in preparation method and easy to standardize; and the use is convenient. The prepared Cp15 recombinant invasive lactic acid bacteria live vector vaccine for preventing cryptosporidiosis can stimulate cellular immunity and humoral immunity of a host and reduce oocyst discharge by 51.7%, which shows that the vaccine has good immune protection capability on cryptosporidium infection.